Wolf Ondracek, CEO

Wolf Ondracek joined Bioneedle Drug Delivery in 2020, bringing more than 25 years of experience in the life sciences industry and clinical development in Europe and APAC. Prior to joining Bioneedle, he was co-founder of 3EACON, a consultancy company offering strategic management and operational support to organizations and companies that are active in the life sciences between East Asia and Western Europe.

As the CEO of Promasys, a clinical data management software systems developer in the Netherlands, he led the acquisition by OmniComm Systems, a US based EDC software company, where he became senior vice-president for APAC and managing director of the Dutch subsidiary. Before joining OmniComm Systems, he was also director business development at the Centre for Human Drug Research in Leiden. In 2008 he was co-founder of Julius Clinical Research, an academic CRO that specializes in large international clinical trials, where he landed a € 100 M contract with a top 5 pharmaceutical company for a global outcomes study.

Wolf brings extensive experience across a broad range of areas to Bioneedle, such as business development and sales, project management and operations, data management, team and organization building, and general management. He has comprehensive knowledge of the different aspects of clinical trials and clinical drug development and has hands-on experience in providing high level management of clinical studies – from small scale, complex early phase trials all the way up to large scale, global outcomes studies. In addition, he has profound knowledge of Japanese (business) culture and language and is an experienced relation builder in other Asian countries. Wolf graduated in social sciences at the Free University in Amsterdam and has a master’s degree in Japanese studies from Leiden University.